23737-51-1

Basic information

• Product Name: solketal tosylate
• Synonyms: solketal tosylate
• CAS NO: 23737-51-1
• Molecular Weight: 286.349
• Mol File: 23737-51-1.mol
• Article Data: 57

Chemical Properties

• CAS DataBase Reference: solketal tosylate(CAS DataBase Reference)
• NIST Chemistry Reference: solketal tosylate(23737-51-1)
• EPA Substance Registry System: solketal tosylate(23737-51-1)

Safety Data

• Hazardous Substances Data: 23737-51-1(Hazardous Substances Data)

Upstream product

• 118712-54-2 glycidyl p-toluenesulfonate 
• 67-64-1 acetone 
• 227945-00-8 diethyl 2-amino-6-[(hydroxycarbamoyl)-methyl]-azulene-1,3-dicarboxylate sodium 
• 104-15-4 toluene-4-sulfonic acid 
• 100-79-8 (R,S)-2,2-dimethyl-1,3-dioxolane-4-methanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 133242-63-4 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-hydroxyphenyl)propionate 
• 110458-42-9 1-[4-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-2-methoxy-ethanone 
• 76098-97-0 C₁₃H₁₄N₂O₂ 
• 130867-76-4 3-Amino-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-5-phenyl-1H-pyrazole-4-carbonitrile 
• 130867-72-0 5-Amino-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-3-phenyl-1H-pyrazole-4-carbonitrile 
• 130867-89-9 1-(2,2-Dimethyl-[1,3]dioxolan-4-ylmethyl)-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 23737-52-2 4-iodomethyl-2,2-dimethyl-[1,3]dioxolane 
• 51704-66-6 (+/-)-2,3-dihydroxypropyl tosylate 
• 196883-49-5 Toluene-4-sulfonic acid 2-pentadecyl-[1,3]dioxolan-4-ylmethyl ester 
• 176643-46-2 2-(4-acetyl-phenyl)-3-(2,2-dimethyl-[1,3]dioxolan-4-yl)-propionic acid ethyl ester 
• 248935-60-6 3-benzyl-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-1H-quinoxalin-2-one 
• 248935-64-0 (+/-)-3-(2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl)-2-phenyl-2,3-dihydrophthalazine-1,4-dione 
• 248935-66-2 (+/-)-5-carbethoxy-3,4-diphenyl-1-(2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl)-1H-pyridazin-6-one 
• 1027627-21-9 1-(2,3-isopropylidene-2,3-dihydroxyprop-1-yl)-2-[(2,3-O-isopropylidene-2,3-dihydroxyprop-1-yl)thio]-4,5-diphenylimidazole 

Relevant articles and documents

Synthesis of alkyl-glycerolipids standards for gas chromatography analysis: Application for chimera and shark liver oils

Natural O-alkyl-glycerolipids, also known as alkyl-ether-lipids (AEL), feature a long fatty alkyl chain linked to the glycerol unit by an ether bond. AEL are ubiquitously found in different tissues but, are abundant in shark liver oil, breast milk, red blood cells, blood plasma, and bone marrow. Only a few AEL are commercially available, while many others with saturated or mono-unsaturated alkyl chains of variable length are not available. These compounds are, however, necessary as standards for analytical methods. Here, we investigated different reported procedures and we adapted some of them to prepare a series of 1-O-alkyl-glycerols featuring mainly saturated alkyl chains of various lengths (14:0, 16:0, 17:0, 19:0, 20:0, 22:0) and two monounsaturated chains (16:1, 18:1). All of these standards were fully characterized by NMR and GC-MS. Finally, we used these standards to identify the AEL subtypes in shark and chimera liver oils. The distribution of the identified AEL were: 14:0 (20–24%), 16:0 (42–54%) and 18:1 (6–16%) and, to a lesser extent, (0.2–2%) for each of the following: 16:1, 17:0, 18:0, and 20:0. These standards open the possibilities to identify AEL subtypes in tumours and compare their composition to those of non-tumour tissues.

Selective catalytic oxidation of diglycerol

The selective oxidation of α,α-diglycerol was studied using oxygen as a clean oxidant in the presence of a palladium/neocuproine complex. After optimization of the reaction parameters, the mono-oxidation product was obtained with 93% NMR yield (up to 76% isolated yield). The product was named “diglycerose” considering that it mainly exists as a cyclic hemi-ketal form.

Ammonium Chloride-Promoted Rapid Synthesis of Monosubstituted Ureas under Microwave Irradiation

Monosubstituted ureas are important scaffolds in organic chemistry. They appear in various biologically active compounds and serve as versatile precursors in synthesis. Monosubstituted ureas were originally prepared using toxic and hazardous phosgene equivalents. Modern methods include transamidation of urea and nucleophilic addition to cyanate salts, both of which suffer from a narrow substrate scope due to the need for a strong acid and prolonged reaction times. We hereby report that ammonium chloride can promote the reaction between amines and potassium cyanate to generate monosubstituted ureas in water. This method proceeds rapidly under microwave irradiation and tolerates a broad range of functional groups. Unlike previous strategies, it is compatible with other nucleophiles, acid-labile moieties, and most of the common protecting groups. The products precipitate out of solution, allowing facile isolation without column chromatography.

NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT

The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.